Ingestion-time – relative to circadian rhythms – differences in the pharmacokinetics and pharmacodynamics of hypertension medications

References

• World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–1992. .
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–e248.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/EHS Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–3104.
   Google Scholar
• Umemura S, Arima H, Arima S, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–1481.
   Google Scholar
• Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36:596–624.
   Google Scholar
• Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183–2189.
   Google Scholar
• Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156–161.
   Google Scholar
• Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036–2045.
   Google Scholar
• Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011;58:1165–1173.
   Google Scholar
• Minutolo R, Agarwal R, Borrelli S, et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med. 2011;171(12):1090–1098. .
   Google Scholar
• Roush GC, Fagard RH, Salles GF, et al. Prognostic impact from clinic, daytime, and nighttime systolic blood pressure in 9 cohorts on 13,844 patients with hypertension. J Hypertens. 2014;32:2332–2340.
   Google Scholar
• Salles GF, Reboldi G, Fagard RH, et al. Prognostic impact of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. Hypertension. 2016;67:693–700.
   Google Scholar
• Hermida RC, Crespo JJ, Otero A, et al. Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention. Eur Heart J. 2018;39:4159–4171.
   Google Scholar
• Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv Drug Deliv Rev. 2007;59:904–922.
   Google Scholar
• Smolensky MH, Hermida RC, Castriotta RJ, et al. Role of sleep-wake cycle on blood pressure circadian rhythms and hypertension. Sleep Med. 2007;8:668–680.
   Google Scholar
• Portaluppi F, Tiseo R, Smolensky MH, et al. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16:151–166.
   Google Scholar
• Fabbian F, Smolensky MH, Tiseo R, et al. Dipper and non-dipper blood pressure 24-hour patterns: circadian rhythm-dependent physiologic and pathophysiologic mechanisms. Chronobiol Int. 2013;30:17–30.
   Google Scholar
• Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood pressure regulation and patterning. Sleep Med Rev. 2017;33:4–16.
   Google Scholar
• Hermida RC, Mojón A, Fernández JR, et al. Ambulatory blood pressure monitoring-based definition of true arterial hypertension. Minerva Med. 2020. in press.
   Google Scholar
• Langner B, Lemmer B. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur J Clin Pharmacol. 1988;33:619–624.
   Google Scholar
• Tateishi T, Fujimura A, Miura T, et al. Chronopharmacological study of furosemide in human subjects. Int J Clin Pharmacol Res. 1988;8:401–407.
   Google Scholar
• Fujimura A, Ohashi K, Sugimoto K, et al. Chronopharmacological study of nitrendipine in healthy subjects. J Clin Pharmacol. 1989;29:909–915.
   Google Scholar
• Jespersen CM, Frederiksen M, Hansen JF, et al. Circadian variation in the pharmacokinetics of verapamil. Eur J Clin Pharmacol. 1989;37:613–615.
   Google Scholar
• Fujimura A, Kumagai Y, Sugimoto K, et al. Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects. Eur J Clin Pharmacol. 1990;38:133–137.
   Google Scholar
• Lemmer B, Nold G, Behne S, et al. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int. 1991;8:485–494.
   Google Scholar
• Weisser K, Schloos J, Lehmann K, et al. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol. 1991;40:95–99.
   Google Scholar
• Fujimura A, Ohira H, Shiga T, et al. Chronopharmacology of furosemide in the elderly. J Clin Pharmacol. 1992;32:838–842.
   Google Scholar
• Hla KK, Latham AN, Henry JA. Influence of time of administration on verapamil pharmacokinetics. Clin Pharmacol Ther. 1992;51:366–370.
   Google Scholar
• Palatini P, Racioppa A, Raule G, et al. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther. 1992;52:378–383.
   Google Scholar
• Koopmans R, Oosterhuis B, Karemaker JM, et al. The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man. Eur J Clin Pharmacol. 1993;44:171–176.
   Google Scholar
• Shiga T, Fujimura A, Tateishi T, et al. The effect of age on diurnal variation in the pharmacokinetics of propanolol in hypertensive subjects. Eur J Clin Pharmacol. 1993;44:489–492.
   Google Scholar
• Shiga T, Fujimura A, Tateishi T, et al. Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects. J Clin Pharmacol. 1993;33:756–761.
   Google Scholar
• Witte K, Weisser K, Neubeck M, et al. Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration. Clin Pharmacol Ther. 1993;54:177–186.
   Google Scholar
• Sunaga K, Fujimura A, Shiga T, et al. Chronopharmacology of enalapril in hypertensive patients. Eur J Clin Pharmacol. 1995;48:441–445.
   Google Scholar
• Kohno I, Ijiri H, Takusagawa M, et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int. 2000;17:209–219.
   Google Scholar
• Khodadoustan S, Ashrafi IN, Satheesh KV, et al. Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. Clin Exp Hypertens. 2017;39:520–526.
   Google Scholar
• Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokin. 1982;7:401–420.
   Google Scholar
• Lemmer B. The clinical relevance of chronopharmacology in therapeutics. Pharmacol Res. 1996;33:107–115.
   Google Scholar
• Bélanger PM, Bruguerolle B, Labrecque G. Rhythms in pharmacokinetics: absorption, distribution, metabolism, and excretion. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Handbook of experimental pharmacology series. Vol. 125. Berlin-New York: Springer-Verlag; 1997. p. 177–204.
   Google Scholar
• Bruguerolle B. Chronopharmacokinetics. Current status. Clin Pharmacokinet. 1998;35:83–94.
   Google Scholar
• Labrecque G, Beauchamp D. Rhythms and pharmacokinetics. In: Redfern P, editor. Chronotherapeutics. London: Pharmaceutical Press; 2003. p. 75–110.
   Google Scholar
• Baraldo M. The influence of circadian rhythyms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 2008;4:175–192.
   Google Scholar
• Hermida RC, Ayala DE, Calvo C, et al. Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev. 2007;59:923–939.
   Google Scholar
• Smolensky MH, Hermida RC, Ayala DE, et al. Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15:173–180.
   Google Scholar
• Hermida RC, Ayala DE, Fernández JR, et al. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011;24:383–391.
   Google Scholar
• Zhao P, Xu P, Wan C, et al. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev. 2011;10:CD004184.
   Google Scholar
• De Giorgi A, Menegatti AM, Fabbian F, et al. Circadian rhythms and medical diseases: does it matter when drugs are taken? Eur J Intern Med. 2013;24:698–706.
   Google Scholar
• Hermida RC, Ayala DE, Fernández JR, et al. Administration-time-differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int. 2013;30:280–314.
   Google Scholar
• Schillaci G, Battista F, Settimi L, et al. Antihypertensive drug treatment and circadian blood pressure rhythm: a review of the role of chronotherapy in hypertension. Curr Pharm Des. 2015;21:756–772.
   Google Scholar
• Smolensky MH, Hermida RC, Ayala DE, et al. Bedtime hypertension chronotherapy: concepts and patient outcomes. Curr Pharm Des. 2015;21:773–790.
   Google Scholar
• Stranges PM, Drew AM, Rafferty P, et al. Treatment of hypertension with chronotherapy: is it time? Ann Pharmacother. 2015;49:323–334.
   Google Scholar
• Hermida RC, Ayala DE, Smolensky MH, et al. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res. 2016;39:277–292.
   Google Scholar
• Sun Y, Yu X, Liu J, et al. Effect of bedtime administration of blood-pressure lowering agents on ambulatory blood pressure monitoring results: a meta-analysis. Cardiol J. 2016;23:473–481.
   Google Scholar
• Hermida RC, Ayala DE, Fernández JR, et al. Bedtime blood pressure chronotherapy significantly improves hypertension management. Heart Fail Clin. 2017;13:759–773.
   Google Scholar
• Bowles NP, Thosar SS, Herzig MX, et al. Chronotherapy for hypertension. Curr Hypertens Rep. 2018;20:97.
   Google Scholar
• Angeli A, Gatti G, Masera R. Chronobiology of the hypothalamic-pituitary-adrenal and renin-angiotensin-aldosterone systems. In: Touitou Y, Haus E, editors. Biologic Rhythms in Clinical and Laboratory Medicine. Berlin: Springer-Verlag; 1992. p. 292–314.
   Google Scholar
• Sothern RB, Vesely DL, Kanabrocki EL, et al. Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Chronobiol Int. 1995;12:106–120.
   Google Scholar
• Yang K, Wang Y, Ding Y, et al. Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats. Chronobiol Int. 2019;36:1058–1071.
   Google Scholar
• Hermida RC, Ayala DE, Smolensky MH, et al. Sleep-time blood pressure: unique sensitive prognostic marker of vascular risk and therapeutic target for prevention. Sleep Med Rev. 2017;33:17–27.
   Google Scholar
• Hermida RC, Smolensky MH, Ayala DE, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM). Chronobiol Int. 2013;30:355–410.
   Google Scholar
• Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. 2009;54:40–46.
   Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, et al. Ambulatory blood pressure monitoring: importance of sampling rate and duration – 48 versus 24 hours – on the accurate assessment of cardiovascular risk. Chronobiol Int. 2013;30:55–67.
   Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, et al. Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int. 2010;27:560–574.
   Google Scholar
• Hermida RC, Calvo C, Ayala DE, et al. Decrease in urinary albumin excretion associated to the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension. 2005;46:960–968.
   Google Scholar
• Hoshino A, Nakamura T, Matsubara H. The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens. 2010;32:416–422.
   Google Scholar
• Kario K, Hoshide S, Shimizu M, et al. Effects of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2010;28:1574–1583.
   Google Scholar
• Eguchi K, Shimizu M, Hoshide S, et al. A bedtime dose of ARB was better than a morning dose in improving baroreflex sensitivity and urinary albumin excretion – the J-TOP study. Clin Exp Hypertens. 2012;34:488–492.
   Google Scholar
• Hermida RC, Calvo C, Ayala DE, et al. Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003;42:283–290.
   Google Scholar
• Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int. 2005;22:755–776.
   Google Scholar
• Hermida RC, Ayala DE, Crespo JJ, et al. Influence of age and hypertension treatment-time on ambulatory blood pressure in hypertensive patients. Chronobiol Int. 2013;30:176–191.
   Google Scholar
• Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005;23:1913–1922.
   Google Scholar
• Kasiakogias A, Tsioufis C, Thomopoulos C, et al. Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. J Hypertens. 2015;33:393–400.
   Google Scholar
• Zappe DH, Crikelair N, Kandra A, et al. Time of administration important? Morning versus evening dosing of valsartan. J Hypertens. 2015;33:385–392.
   Google Scholar
• Hermida RC, Ayala DE, Fernández JR, et al. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension. 2007;50:715–722.
   Google Scholar
• Hermida RC, Ayala DE, Mojón A, et al. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens. 2008;21:948–954.
   Google Scholar
• Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629–1651.
   Google Scholar
• Hermida RC, Ayala DE, Mojón A, et al. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol Int. 2013;30:315–327.
   Google Scholar
• Hermida RC. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: rationale and design of the Hygia Project. Chronobiol Int. 2016;33:906–936.
   Google Scholar
• Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial. Eur Heart J. 2019 Oct 22. DOI:10.1093/eurheartj/ehz754.
   Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764.
   Google Scholar
• Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Syst-China) collaborative group. J Hypertens. 1998;16:1823–1829.
   Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145–153.
   Google Scholar
• Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603.
   Google Scholar
• Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA. 2003;289:2073–2082.
   Google Scholar
• Roush GC, Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens (Greenwich). 2014;16:561–568.
   Google Scholar
• Gupta R, Malik AH, Popli T, et al. Impact of bedtime dosing of antihypertensives compared to morning therapy: A meta-analysis of randomised controlled trials. Eur J Prev Cardiol. 2020 Feb 3. DOI:10.1177/2047487320903611.
   Google Scholar
• Sobiczewski W, Wirthwein M, Gruchala M, et al. Mortality in hypertensive patients with coronary heart disease depends on chronopharmacotherapy and dipping status. Pharmacol Rep. 2014;66:448–452.
   Google Scholar
• Rorie DA, Rogers A, Mackenzie IS, et al. Methods of a large prospective, randomized, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. BMJ Open. 2016;6:e010313.
   Google Scholar
• Kim SYH, Miller FG. Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugs. Clin Trials. 2015;12:557–563.
   Google Scholar
• Hermida RC, Mojón A, Fernández JR. Comparing the design of the primary-care based Hygia chronotherapy trial and the internet-based TIME study. Eur Heart J. 2020;41:1608.
   Google Scholar
• Portaluppi F, Trasforini G, Margutti A, et al. Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J Hypertens. 1992;10:1227–1234.
   Google Scholar
• Kanabrocki EL, George M, Hermida RC, et al. Day-night variations in blood levels of nitric oxide, T-TFPI and E-selectin. Clin Appl Thrombosis/Hemostasis. 2001;7:339–345.
   Google Scholar
• Sole MJ, Martino TA. Diurnal physiology: core principles with application to the pathogenesis, diagnosis, prevention, and treatment of myocardial hypertrophy and failure. J Appl Physiol. 2009;107:1318–1327.
   Google Scholar
• Martino TA, Tata N, Simpson JA, et al. The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy. J Am Coll Cardiol. 2011;57:2020–2028.
   Google Scholar
• Rana S, Prabhu SD, Young ME. Chronobiological influence over cardiovascular function. The good, the bad, and ugly. Circ Res. 2020;126:258–279.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care. 2012;35(Suppl 1):S11–S63.
   Google Scholar
• Rydén L, Grant PJ, Anker SD, et al. The task force of diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD). ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2013;34:3035–3087.
   Google Scholar
• Hermida RC, Crespo JJ, Domínguez-Sardiña M, for the Hygia Chronotherapy Trial investigators. Improved reduction of cardiovascular risk by bedtime ingestion of ARB and ACEI medication class therapies. Eur Heart J. 2020;41:1602–1603.
   Google Scholar
• Crespo JJ, Domínguez-Sardiña M, Otero A, et al. The Hygia project and Hygia chronotherapy trial: insights of we clinical investigators on the impact of the embedded continuing medical education on primary care practice and improved patient cardiovascular health. Chronobiol Int. 2020. in press. DOI:10.1080/07420528.2020.1771357.
   Google Scholar
• Hermida RC, Ayala DE, Mojón A, et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:1270–1276.
   Google Scholar
• Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313–2321.
   Google Scholar
• Ayala DE, Hermida RC, Mojón A, et al. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int. 2013;30:340–352.
   Google Scholar